CJC-1295 (without DAC) vs Dutasteride
Well Studied vs FDA Approved
monitor Mechanism-based · 51% Both CJC-1295 (without DAC) and Dutasteride can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed.
Molecular Data
CJC-1295 (without DAC) Dutasteride
Weight 3,367.97 Da 528.53 Da
Half-life 30 minutes - 2 hours ~5 weeks (extremely long; active metabolite accumulation over months)
Chain 30 amino acids —
Type GHRH analog Synthetic 4-azasteroid compound (dual 5-alpha reductase inhibitor)
Key Benefits
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
Dutasteride
01 Inhibits both Type I and Type II 5-alpha reductase for more complete DHT suppression
02 Reduces serum DHT by approximately 90%, compared to 70% with finasteride
03 Head-to-head trials show superior hair count improvements over finasteride at 12 and 24 weeks
04 FDA-approved for BPH with well-established long-term safety data
05 Extremely long half-life allows for flexible dosing schedules (daily or 3x per week)
06 Convenient once-daily oral dosing with no injections required
07 Can be combined with minoxidil for enhanced hair loss treatment
Dosing Protocols
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
Dutasteride
0.5mg/day / Once daily or 3x per week
Side Effects
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
Dutasteride
Decreased libido (reported in 3-5% of men; somewhat higher incidence than finasteride due to greater DHT suppression)
Erectile dysfunction (reported in 3-5%; more frequently reported than with finasteride)
Decreased ejaculate volume (reported in 1-2%)
Gynecomastia or breast tenderness (reported in approximately 1-2%)
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Women who are pregnant or may become pregnant (dutasteride is teratogenic and can cause abnormalities of external genitalia in a male fetus; even handling damaged capsules poses a risk due to skin absorption)
Women who are breastfeeding
Known hypersensitivity to dutasteride, other 5-alpha reductase inhibitors, or any component of the formulation
Severe hepatic impairment (dutasteride is extensively metabolized by the liver via CYP3A4)
Pediatric patients (not indicated for use in children)
Co-administration with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) may significantly increase dutasteride levels
Research Evidence
CJC-1295 (without DAC) Dutasteride
Status Well Studied FDA Approved
References 5 studies 5 studies
Latest November 2024 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.